Determinants of Phage Host Range in *Staphylococcus* Species

Abraham G. Moller[a,c], Jodi A. Lindsay[b], and Timothy D. Read[c*]

a. Program in Microbiology and Molecular Genetics (MMG), Graduate Division of Biological and Biomedical Sciences (GDBBS), Emory University School of Medicine, Atlanta, Georgia, 30322

b. Institute of Infection and Immunity, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK

c. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, 30322

*Corresponding author – tread@emory.edu

Abstract

Bacteria in the genus *Staphylococcus* are important targets for phage therapy due to their prevalence as pathogens and increasing antibiotic resistance. Here we review *Staphylococcus* outer surface features and specific phage resistance mechanisms that define host range - the set of strains an individual phage can potentially infect. Phage infection goes through five distinct phases - attachment, uptake, biosynthesis, assembly and lysis. Adsorption inhibition, encompassing outer surface teichoic acid receptor alteration, elimination, or occlusion, limits successful phage attachment and entry. Restriction-modification systems (in particular, type I and IV systems), which target phage DNA inside the cell, serve as the major barriers to biosynthesis as well as transduction and horizontal gene transfer between clonal complexes and species. Resistance to late stages of infection occurs through mechanisms such as assembly interference, in which staphylococcal pathogenicity islands siphon away superinfecting phage proteins to package their own DNA. While genes responsible for teichoic acid biosynthesis, capsule, and restriction-modification are found in most *Staphylococcus* strains, a variety of other host-range determinants (e.g., CRISPRs, abortive infection, and superinfection immunity) are sporadic. Fitness costs of phage resistance through teichoic acid structure alteration could make staphylococcal phage therapies promising, but host range prediction is complex because of the large number of genes involved, many with unknown roles. In addition, little is known about genetic determinants that contribute to host range expansion in the phages themselves. Future research must identify

host range determinants, characterize resistance development during infection and treatment, and examine population-wide genetic background effects on resistance selection.

Keywords: staphylococci, phage resistance, host range, phage therapy, CRISPR

Introduction

The *Staphylococcus* genus includes commensals and pathogens of humans and animals. *S. aureus* and *S. epidermidis*, in particular, cause diverse infections in humans and have become increasingly antibiotic resistant over the past seventy years. Diseases range from food poisoning to skin and soft tissue infections, pneumonia, osteomyelitis, endocarditis, and septic shock. *S. aureus* is carried by between 20% (persistently) and 60% (intermittently) of the human population (1), primarily on the skin and upper respiratory tract. Methicillin-resistant *S. aureus* (MRSA) emerged in the mid-1960s (2) and has reduced the options for treatment with beta-lactam antibiotics. The combination of high carriage rates, diverse pathologies, prevalent antimicrobial resistance, and lack of a licensed vaccine (3) makes staphylococcal species important targets for new therapies.

Bacteriophage (phages) are natural killers of *Staphylococcus* bacteria lysing bacterial cells through expression of holins, which permeabilize the membrane and release endolysins (4, 5) that degrade the peptidoglycan of the cell wall (6). Phage therapy is a promising alternative to antibiotics for treating infections because of the large number of diverse phages with low toxicity to humans and non-target species (7, 8).

Phage therapy has a long history, reaching back before the antibiotic era to shortly after the discovery of phages themselves by Frederick Twort and Felix d'Herelle in the 1910s (9–11). While overshadowed by the subsequent discovery of antibiotics and generally abandoned in the West for many years, phage therapy persisted as a bacterial treatment in eastern Europe and the nations that composed the former Soviet Union (9, 10). There, phage cocktails were developed for sepsis, osteomyelitis, and burn wounds, among other staphylococcal diseases, with complete recovery reported in some cases (12). Polish and Soviet studies showed that phage lysates effectively treated staphylococcal skin and lung infections (13). More recently, the emergence of multi-drug resistance in bacterial pathogens has renewed interest in phage therapy and phage biology (8, 14). Safety studies on the staphylococcal phage lysate (SPL) as well as phage cocktails containing *S. aureus*-specific phages indicated that they had no adverse effects when administered intranasally,

intravenously, orally, topically, or subcutaneously (14). Phages have also been recently approved by the FDA as a treatment to clear another Gram-positive species (*Listeria monocytogenes*) present in food (15) and approved as personalized treatment for burn wound infections (16).

All known staphylococcal phages are members of the order *Caudovirales* with linear dsDNA virion genomes. Staphylococcal phages are divided into three families with distinctive morphologies – the long, noncontractile-tailed *Siphoviridae*, the contractile-tailed *Myoviridae*, and the short, noncontractile-tailed *Podoviridae* (17, 18). *Siphoviridae* genomes are 39-43 kb in size, while those of the *Myoviridae* are 120-140 kb and *Podoviridae* are 16-18 kb (17). Currently reported *Siphoviridae* are typically temperate phages that encode lysogeny functions within a genomic module, while reported *Myoviridae* and *Podoviridae* are virulent. The virulent phages are the strongest potential candidates for phage therapy, given that they are not known to lysogenize and thus obligately kill their targets. Lytic staphylococcal phages have surprisingly broad host ranges (19–22), anti-biofilm activity (19, 23), and varying effectiveness against infection (24–26). The *Siphoviridae* are agents of horizontal gene transfer (HGT) through transduction (27) into recipient strains (17) and activation of staphylococcal pathogenicity islands (SaPIs) (28). The *Siphoviridae* have been subdivided into “integrase types” based on the sequence of the integrase gene necessary for lysogenic insertion into the chromosome (17, 29). Certain integrase type phages introduce specific virulence factors (17). Integrase type 3 (Sa3int) phages encode the immune evasion cluster (IEC), which includes the staphylokinase (*sak*), staphylococcal complement inhibitor (*scn*), chemotaxis inhibitory protein (*chp*), and enterotoxin S (*sea*). In addition, Sa2int phage often encode Panton-Valentine leukocidin (*lukFS-PV*), while Sa1int phages often encode exfoliative toxin A (*eta*). Temperate staphylococcal phages can also disrupt chromosomal virulence factors (17). Sa3int and Sa6int phages, for example, integrate into sites in the beta-hemolysin (*hlb*) or lipase (*geh*) genes, respectively (30, 31).

No single phage can kill every *Staphylococcus* strain. Instead, each phage has a particular host range, defined as the set of strains permissive for its infection. Host range can be limited by active host resistance mechanisms such as CRISPR or restriction-modification that actively suppress phage infection or by passive mechanisms such as loss of receptors for phage adsorption. It is unclear whether these host range limiting factors have arisen through specific adaptation against phage infection or are byproducts of selection against other stresses. There are, however, specific phage counteracting mechanisms to host resistance that serve to

broaden phage host range. Phage host range has great importance to phage therapy because it defines the potential scope of treatable strains, thus informing selection of phages for rational, personalized cocktail development.

Mechanisms of resistance to phage have been reviewed previously across bacteria generally (32, 33) and in lactic acid bacteria (34), but this is the first article to focus on the particular features of *Staphylococcus* (**Figure 1**). By far, the majority of the literature has focused on two species: *S. epidermidis*, and especially, *S. aureus*. However, we include studies on other species (e.g. *S. simulans*) where appropriate. We then reflect on possible consequences of resistance on phage host range and potential phage therapy for staphylococcal infections, given that phage resistance elements determine host range and thus provide one criterion for phage efficacy in therapy. We also consider the evolutionary trade-offs of phage resistance in a therapeutic context due to the potential effects of phage resistance on either virulence or antibiotic resistance.

Host resistance can occur at different points in the phage life cycle (**Figure 1**) (32, 33). There are no reports in *Staphylococcus* of mechanisms that limit host range at the uptake and host lysis phases. We therefore concentrate on the attachment, biosynthesis, and assembly phases.

Attachment

Wall teichoic acid is the primary staphylococcal phage receptor

Attachment of phages to the outside of the *Staphylococcus* cell (**Figure 2A**) is the first stage of infection (**Figure 1**). *Staphylococcus* may be resistant to phage adsorption if the receptor molecule is not present, not recognized by the phage, or blocked. Mutations that alter components of the outer surface can have the effect of inhibiting adsorption and thus conferring resistance. Through genetic and biochemical studies on a small range of staphylococcal phages, the polyribitol phosphate (poly-RboP) polymer of wall teichoic acid (WTA) or N-acetylglucosamine (GlcNAc) modifications at the 4 positions of ribitol phosphate monomers in WTA appear to be the primary targets (35–41).

In an early *S. aureus* phage resistance study published in 1969, N-methyl-N'-nitro-N-nitrosoguanidine-mutagenized strain H (Multi Locus Sequence Type 30; ST30) (42) phage-resistant mutants were selected by plating on agar plates containing lawns of 52A (siphovirus) (40). Mutants also found resistant to phage K

(myovirus) were deficient in N-acetylglucosamine, cell wall phosphorus, and ester-linked D-alanine in their envelopes, presumably due to a loss of wall teichoic acid production. Further biochemical characterization showed that the mutants lacked UDP-GlcNAc:polyribitol phosphate transferase activity and WTA. Counterintuitively, they did show the relevant biochemical activity for the last known step in WTA biosynthesis (phosphoribitol transferase – TarL, **Figure 2B**) (38). This surprising result suggested the double resistant mutants produced ribitol phosphate but either failed to properly polymerize WTA or attach it to the cell wall. These mutants had pleiotropic phenotypic differences from their parent strain (41), including a longer generation time than its parent; cell growth in clumps; irregular, rough, gray colonies; and increased levels of wall-bound autolysin. A later study characterizing spontaneous *S. aureus* strain A170 (ST45) mutants resistant to siphovirus M^{Sa} found similar phenotypic defects (43) and biochemical assays also showed that resistance was likely due to the lack of GlcNAc-modified WTA.

Peschel and colleagues identified genes responsible for phage adsorption in a series of elegant molecular genetic studies in the RN4220 (ST8) (44) background (35, 36, 45). Deletion of undecaprenyl-phosphate N-acetylglucosaminyl 1-phosphate transferase (*tagO*), the first gene involved in WTA biosynthesis, conferred resistance and reduced adsorption to tested *Myoviridae* (Φ812 and ΦK), while a transposon insertion mutant in the *tarM* gene had resistance and reduced adsorption to *Siphoviridae* (ΦSa2mw, Φ47, Φ13, and Φ77). Complementation of wild-type alleles rescued these phenotypes (35). TarM is a glycosyltransferase responsible for attaching α-O-GlcNAc to the 4 position of the ribitol phosphate WTA monomer (46, 47). The *tarM* mutant was previously shown to lack GlcNAc-modified WTA in its envelope (46). TarS, the glycosyltransferase responsible for attaching β-O-GlcNAc to the 4 position of the ribitol phosphate WTA monomer (48), was specifically required for podovirus adsorption (45). Deletion of *tarS* conferred resistance and reduced adsorption to tested *Podoviridae* (Φ44AHJD, Φ66, and ΦP68) (45), but only deletion of both *tarS* and *tarM* conferred reduced adsorption to tested *Siphoviridae* (Φ11) in the same RN4220 background used in prior studies (49, 50). On the other hand, even *tarS*+, *tarM*+ strains were resistant to *Podoviridae*, suggesting WTA decorated with α-O-GlcNAc by TarM impeded podovirus adsorption (45). Taken together, these findings suggested, for the small number of representatives that were tested, elimination of WTA confers resistance to all classes of phage, elimination of GlcNAc modifications confers resistance to the *Siphoviridae* and *Podoviridae*, and elimination of β-O-GlcNAc modification confers resistance specifically to the *Podoviridae*.

Given the conservation of wall teichoic acid biosynthesis genes amongst *S. aureus* genomes (51) and the cross-species activity of staphylococcal phages such as phage K (52), these conclusions could be expected to hold in staphylococci beyond *S. aureus*.

Recent studies have suggested that as the number of strains and phages expands we may find a larger number of genes influencing host range through attachment. Azam et al. conducted a long-term evolution experiment in which they selected *S. aureus* SA003 (ST352) mutants resistant to myovirus ΦSA012 (53). Resistant mutants gained missense mutations in five genes (*tagO*, RNase adapter protein *rapZ*, putative membrane protein *yozB*, guanylate kinase *gmk*, and alpha subunit of DNA-dependent RNA polymerase *rpoA*), a nonsense mutation in one gene (UDP-N-acetylglucosamine 1-carboxyvinyltransferase *murA2*), and a 1,779 bp deletion that included the C-terminal region of the teichoic acid glycosyltransferase *tarS*, a non-coding region, and the N-terminal region of the iron-sulfur repair protein *scd*. Complementation of mutations in genes *scd*, *tagO*, *rapZ*, and *murA2* restored ΦSA012 sensitivity and adsorption, while only complementation of mutations in *tarS* restored sensitivity and adsorption of another myovirus, ΦSA039. The results suggested that while ΦSA012 recognized the WTA backbone, ΦSA039 was unusual in recognizing β-O-GlcNAc-modified WTA, hinting that there may be more variability in receptor targets within phage groups than the limited number of earlier studies suggested.

The carriage of a prophage in certain *S. aureus* CC5 and CC398 strains that encodes alternative WTA glycosyltransferase *tarP* (54) adds further complications. TarP attaches GlcNAc to the 3 position of ribitol phosphate rather than the 4 position, thus conferring *Siphoviridae* (Φ11, Φ52a, Φ80) sensitivity but *Podoviridae* (Φ44, Φ66, and ΦP68) resistance. It is interesting in the light of host range evolution that a gene carried on a prophage can change the properties of the *S. aureus* surface and thus affect the host ranges of other phages.

Although the majority of staphylococcal phage tested bind WTA and GlcNAc receptors, there is one known exception. Siphovirus Φ187 binds WTA glycosylated with N-acetyl-D-galactosamine (GalNAc), the unusual WTA synthesized by *S. aureus* ST395 (55). The α-O-GalNAc transferase *tagN*, the nucleotide sugar epimerase *tagV*, and the short GroP WTA polymerase *tagF* genes are required specifically for synthesis of ST395 WTA. Homologs of these genes were found in genomes of multiple Coagulase-Negative *Staphylococci* (CoNS) strains, such as *S. pseudointermedius* ED99, *S. epidermidis* M23864:W1, and *S. lugdunensis*

N920143. Complementation of a *S. aureus* PS187 *tagN* C-terminal glycosyltransferase deletion with the wild-type *tagN* gene or that from *S. carnosus* (*tagN*-Sc) successfully restored the wild-type phenotype, suggesting *tagN* homologs in other CoNS genomes had similar functions to that in *S. aureus* PS187 (ST395). Complementation of the *tagN* C-terminal deletion with either PS187 or *S. carnosus tagN* also restored wild-type Φ187 sensitivity. This difference in WTA structure was shown to prohibit transduction between ST395 and other *S. aureus* lineages (56). Staphylococcal pathogenicity island (SaPI) particles prepared in a ST1, 5, 8, 22, 25, or 30 strain with phages Φ11 or Φ80α failed to transduce any ST395 strains. SaPI particles prepared in a ST395 strain, on the other hand, transduced other ST395 strains as well as CoNS species and *Listeria monocytogenes*. These findings suggest the unique ST395 WTA restricts phage host range to strains of the same sequence type or Gram-positives with a related WTA structure, such as *Listeria monocytogenes*.

There has been one study showing that staphylococcal phages (siphovirus ΦSLT) can bind lipoteichoic acid (LTA), the lipid-anchored, polyglycerol phosphate (GroP) TA polymer (57) (**Figure 2A**). However, subsequent elimination of LTA biosynthesis through *ltaS* deletion had no effect on phage adsorption or sensitivity (35) and therefore the potential significance of LTA as an alternative receptor is currently unknown.

The effects of surface proteins and extracellular polysaccharides on attachment

Although proteins serve as receptors for many Gram-positive phages (for example, the YueB receptor for *Bacillus subtilis* phage SPP1 (58)), there is no evidence to suggest *S. aureus* proteins serve as its phage receptors. Phage interaction protein (Pip) homologs exist throughout the Gram-positives, serving as protein receptors to which phage irreversibly bind (59). There are Pip surface protein homologs anchored to the staphylococcal cell wall through the action of the sortase enzyme in *Staphylococcus* (60, 61). However, neither deletion of the Pip homologs in RN4220 (ST8) (49) nor sortase A in Newman (ST254) (62, 63) affected sensitivity to phage Φ11 and phages ΦNM1, ΦNM2, and ΦNM4, respectively.

Some classes of proteins or extracellular polysaccharides have been shown to block phage adsorption in the staphylococci through occlusion of the WTA receptors. Overproduction of surface protein A in *S. aureus* was shown to reduce phage adsorption through this mechanism (64), but work on surface protein occlusion remains limited. Capsule types 1 and 2 - strains M (ST1254) (42) and Smith diffuse (ST707) (42), respectively - were shown to occlude adsorption (65), but the most common capsule types, 5 and 8, showed inconclusive

results (66, 67). Differences in capsule thickness between strains may account for these variable results. Type 1 and 2 strains are mucoid and heavily encapsulated, while type 5 and 8 are non-mucoid despite encapsulation (68). The CoNS species *Staphylococcus simulans* also showed capsule-dependent inhibition of phage adsorption (69).

The exopolysaccharides (EPS) of staphylococcal biofilms have not been shown to occlude adsorption. Surface proteins, such as biofilm-associated protein (Bap), exopolysaccharides (polysaccharide intercellular adhesin - PIA - composed of poly-N-acetylglucosamine – PNAG – and synthesized by the products of the *icaADBC* operon), and extracellular DNA (eDNA) compose staphylococcal biofilms, which can form by PIA-dependent or protein (Bap)-dependent mechanisms (70, 71). Other surface proteins more common than Bap can also mediate biofilm formation, such as FnbA/FnbB (72, 73) and SasG (74) in *S. aureus* and Aap in *S. epidermidis* (70). Both *S. aureus* (19, 75) and *S. epidermidis* (52, 76, 77) biofilms are susceptible to phage predation. Phage resistance in staphylococcal biofilms may instead be associated with altered biofilm diffusion or metabolism, the latter of which resembles stationary phase growth. Studies on *S. epidermidis* suggested phage susceptibility was similar in biofilms and stationary phase cultures (52). Phages may in fact promote bacterial persistence in *S. aureus* biofilms by releasing nutrients from lysed cells for remaining live ones to utilize (78).

Biosynthesis

Superinfection immunity

Staphylococcal temperate phages encode homologs of the cI repressor (17, 18). In *E. coli*, this protein represses expression of the lytic cycle in newly infecting phages with the same cI protein-binding sites, thus stopping new infections through a mechanism called superinfection immunity. Molecular and evolutionary studies on the *E. coli* phage lambda model suggest many superinfection immunity groups (in which member temperate phages confer immunity to each other upon integration) coexist in nature (79), with cI repressor – operator coevolution driving the emergence of new immunity groups (80). Superinfection immunity as a determining factor in phage host range in staphylococcal species appears not to have been studied yet, but since prophages are common (most sequenced *S. aureus* genomes contain 1-4 prophages) (18, 81), it may be a significant barrier to phage infection.

Restriction-modification (R-M) systems

Bacteria can resist phage infection by degrading injected phage DNA before it has the chance to replicate and enter the lytic or lysogenic cycle (**Figure 1**). Restriction-modification (R-M) is a prominent phage infection barrier in the *Staphylococcus* genus. R-M systems are modular operons containing combinations of host specificity determinant (*hsd*) genes encoding three types of functions: restriction endonuclease activity (*hsdR*) responsible for destroying unmodified DNA, DNA adenosine or cytosine methyltransferase activity (*hsdM*) responsible for modifying host DNA so that it is not cleaved by restriction endonucleases, and specificity DNA-binding proteins (*hsdS*) responsible for recognizing sequence motifs targeted for cleavage or modification (82).

There are four known types of R-M systems in bacteria, all of which have been found in the staphylococci (83). In type I systems, the restriction enzyme cleaves unmodified DNA adjacent to its binding site, sometimes separated by as much as 1000 bp from the binding site, while the modification enzyme methylates host DNA at the target site specified by the specificity protein. A complex containing all three types of subunits restricts unmodified exogenous DNA, while HsdSHsdM complexes only modify DNA. In type II systems, the restriction enzyme ($HsdR_2$) cleaves unmodified DNA at its binding site, while the modification enzyme (HsdM) modifies DNA at this site. In type III systems, the restriction enzyme cleaves unmodified DNA roughly 24-28 bp downstream from its asymmetric target site, while the modification enzyme methylates a single strand of host DNA at the target site. The modification subunit (Mod) modifies one strand of DNA either by itself (Mod_2) or in complex with the restriction subunit (e.g., Mod_2Res_1 or Mod_2Res_2), while the restriction subunit (Res) cleaves unmodified DNA only in complex with modification subunits (Mod_2Res_1 or Mod_2Res_2). In type IV systems, the restriction enzyme only cleaves modified, methylated DNA. Type IV systems do not include a modification enzyme. These systems have been well studied in *S. aureus* (and in *S. epidermidis*, to a more limited extent) due to their role in restricting natural horizontal gene transfer and genetic manipulation of the organism (83–86).

Type I R-M systems are the most abundant class of R-M systems reported in *S. aureus*, followed by type IV and then type II systems (83). Type III systems appear to be rare, with only two described in the genus (83). Analyses of the restriction enzyme genomic database REBASE in 2014 showed that all completed *S.*

aureus genomes encode a type I R-M system and that most *S. aureus* genomes annotated with R-M genes encode a type I system (83, 87). The most common type I R-M locus found in *S. aureus* is Sau1 (88). Expressing a functional Sau1 *hsdR* gene in restriction-deficient *S. aureus* strain RN4220 greatly reduced electroporation, conjugation, and transduction frequencies (88). *S. aureus* genomes generally encode two Sau1 *hsdS* genes that specify two distinct DNA motif targets for restriction or modification (89). The Sau1 HsdS subunit determines target specificity through its two target recognition domains (TRDs), which each bind to one part of the target sequence (90). TRDs are the least conserved portions of the HsdS amino acid sequences (88), and vary in carriage between strains with lineage and/or clonal complex-specific variant associations, as microarray hybridization studies indicate (88, 89). The Sau1 system prevented transfer of plasmid DNA from one clonal complex (CC5) to another (CC8) with a different target recognition site (89), showing that restriction defines barriers between clonal complexes. Sau1 also affected susceptibility of two CC8 strains (NCTC8325-4 and RN4220 p*hsdR*) but not the *hsdR*-deficient RN4220 to phage Φ75 (siphovirus) propagated in a CC51 strain (879R4RF), suggesting Sau1 can control phage host range (88). Sau1 variation is a powerful marker of lineage/clonal complex (88, 91) and likely drives the independent evolution of clonal complexes. Sau1 would therefore be predicted to be a major host range limitation to phages grown in a strain of a different clonal complex. Since the target sites of nearly all *S. aureus* Sau1 R-Ms from each of the different clonal complexes have now been identified (90), it should be possible to bioinformatically predict the Sau1-defined clonal complex host range of any sequenced bacteriophage.

Type IV R-M system SauUSI is estimated to be found in 90% of *S. aureus* strains (83, 92) and, in combination with Sau1, presents an effective restriction barrier for resisting phage infection (93). SauUSI specifically restricts DNA methylated or hydroxymethylated at the C5 position of cytosine (92). The preferred binding site for SauUSI is Sm5CNGS, where S represents either cytosine or guanine (92). Type II R-M systems have been estimated to be in ~33% of strains and display a range of target sites (83, 94–96). The most common type II R-M system found in *S. aureus* is called Sau3A (94). The Sau3A restriction enzyme cleaves 5’ to the guanine in unmodified 5’-GATC-3’ sequences. The Sau3A modification enzyme, on the other hand, methylates the restriction site at the C5 position of cytosine (97). Some type II systems, such as Sau42I, are encoded by phages. Sau42I is an example of a type IIS R-M system, which binds asymmetric DNA sequences and cleaves outside the recognition site, unlike most type II systems (82). Unlike type I and type IV,

type II systems are often carried on mobile genetic elements which are capable of frequent transfer between strains and are not conserved amongst all members of the same clonal complex, so they present a more strain-specific and variable limit to host range (87). Certain *S. aureus* type II R-M systems (e.g., Sau96I) serve to negate the Type IV SauUSI system because they methylate cytosines and guanines in sequences SauUSI targets for cleavage. This is an interesting example of how R-M systems acquired by HGT can have unpredictable interactions with existing systems.

If unmodified phages can survive restriction enzyme degradation upon cell entry, the phage DNA molecules acquire protective DNA methylation as they replicate. While survival of restriction can happen stochastically at high multiplicities of infection, phages have also been shown to have evolved or acquired adaptations for restriction evasion. Anti-restriction mechanisms include restriction site alteration, restriction site occlusion, indirect subversion of restriction-modification activity, and direct inhibition of restriction-modification systems (98). Restriction site alteration can include both incorporation of alternative bases, such as 5-hydroxymethyluracil (5hmU) and 5-hydroxymethylcytosine (5hmC), and loss of restriction sites through selection. A clear example of the latter in the staphylococci is the elimination of GATC sites in the 140 kb phage K genome, enabling its avoidance of Sau3A restriction (99). Another example is the evolution of particular antimicrobial resistance-carrying conjugative plasmids which have lost specific Sau1 R-M sites allowing their transfer between common MRSA lineages (88). Restriction site occlusion refers to DNA-binding proteins preventing restriction enzymes from binding and digesting DNA (98, 100, 101). R-M subversion either occurs through stimulation of host modification enzymes or destruction of restriction cofactors (e.g., SAM) (98, 102, 103). R-M inhibition occurs most often in type I systems (but also in some type II systems) through the binding of specific anti-restriction proteins, such as ArdA, ArdB, and Ocr (98, 104, 105). There is no literature specifically characterizing anti-restriction in *Staphylococcus*, but an *E. coli ardA* homolog has been identified in the staphylococcal Tn916 and Tn5801 transposons (106).

Clustered regularly interspaced short palindromic repeat (CRISPR) systems

CRISPRs confer immunity to phage infection through the cleavage of extrinsic DNA in a sequence-specific manner. Unlike R-M systems, which target specific DNA sequence motifs, CRISPRs adaptively incorporate target sequences from phages they have destroyed to increase the efficiency of protection. After

integrating short segments of foreign DNA as spacers of CRISPR arrays, CRISPR-associated (Cas) nucleases process the transcribed CRISPR array RNA into CRISPR RNAs (crRNAs) used to target new incursions of identical foreign DNA elements for destruction (107, 108). Surveys of *S. aureus* and *S. epidermidis* genomes indicate CRISPRs are not common in these species (109, 110). These surveys looked for the presence of *cas6* and *cas9* genes, which are nucleases required for Type I/III and Type II CRISPR-mediated resistance, respectively. Cas6 is an endoribonuclease found in Type I and III CRISPR systems that cleaves pre-crRNA transcripts within the 3' end of the repeat region to produce mature guide crRNAs (111, 112), while Cas9 is an endonuclease found in Type II CRISPR systems that cleaves DNA in a crRNA-guided manner (112, 113). Only 12 of 300 published *S. epidermidis* genomes searched encoded the Cas6 nuclease, 18 of 130 *S. epidermidis* isolates from Denmark (Copenhagen University Hospital) tested positive for *cas6* via PCR, and 14 of nearly 5000 published *S. aureus* genomes encoded CRISPR/Cas systems (109). Another study specifically examining *S. aureus* found that 2 of 32 *S. aureus* strains encoded CRISPR/Cas systems (110). These CRISPRs were similar to those found in two *S. lugdunensis* strains, suggesting they were recombined with *S. lugdunensis* or derived from a common ancestor (110). CRISPR/Cas systems have also occasionally been reported in strains of other species (*S. capitis*, *S. schleifer*, *S. intermedius*, *S. argenteus*, and *S. microti*) (109). Only a single *S. aureus* strain has been reported to encode Cas9, which is found in an SCCmec-like region (114). Nonetheless, CRISPR systems have been shown to be important in resisting introduction of foreign DNA in *S. epidermidis* RP62a (115, 116). Anti-CRISPR mechanisms, such as proteins that prevent CRISPR-Cas systems from binding DNA target sites, are being discovered in many phages (117–119), although not yet in those specific for staphylococci. Currently discovered anti-CRISPR mechanisms have been shown to target both type I and type II CRISPR systems (117–120).

Assembly

Assembly interference is the parasitization of superinfecting phage by chromosomal phage-like elements and has been demonstrated experimentally in *S. aureus* pathogenicity island (SaPI)-helper phage interactions. SaPIs encode important virulence factors, such as toxic shock syndrome toxin (TSST), but are only mobilized by superinfecting helper siphoviruses (28, 121). The Dut dUTPase protein expressed by helper phages derepresses the StI SaPI repressor, activating the SaPI lytic cycle (28). The derepressed SaPIs then take advantage of the superinfection to proliferate at the expense of the helper phage. SaPIs interfere with

helper phage assembly through several mechanisms (122) - remodeling phage capsid proteins to fit the small SaPI genome (123–127), encoding phage packaging interference (Ppi) proteins that prevent helper phage DNA packaging into new SaPI particles (123), and disrupting phage late gene activation (128). All known SaPIs encode phage packaging interference (Ppi) proteins, which divert phage DNA packaging toward SaPIs by inhibiting helper phage terminase small subunits ($TerS_P$) but not corresponding SaPI subunits ($TerS_S$) (123). Ppi proteins are divided into two classes based on sequence that differ in helper phage specificity – Class I interferes with Φ80α and Φ11, while Class II interferes with Φ12 (123). The PtiM-modulated PtiA and the PtiB SaPI2 proteins inhibit expression of the LtrC-activated phage 80 late gene operon (packaging and lysis genes), thus interfering with later steps of the helper phage life cycle (128). The SaPI particles then go on to infect new *S. aureus* hosts, integrating their DNA into the chromosome instead of killing the cell. Helper phages and SaPIs are thought to gain and lose resistance to each other in a 'Red Queen' scenario, given the observed rapid co-evolution of their respective *dut* and *stl* genes (129). SaPIs are found throughout *Staphylococcus* species and beyond; therefore, they may be a common strain-specific modifier of siphovirus infection potential.

Other phage host range limiting factors

Several uncommon or less well-understood mechanisms may contribute to phage host range limitation in *Staphylococcus*. One abortive infection (Abi) system, the eukaryotic-like serine/threonine kinase Stk2, has been characterized in *S. aureus* and *S. epidermidis* (130). In this case, siphovirus infection results in self-induced killing of the host cell, preventing the amplification and spread of phages in the population. Stk2 was found to be activated by a phage protein of unknown function and caused cell death by phosphorylating host proteins involved in diverse core cellular functions. Only *S. epidermidis* RP62A and a few *S. aureus* strains encode Stk2, however, suggesting limited genus-wide importance. The recent long-term evolution study on *S. aureus* strain SA003 uncovered two genes involved in post-adsorption resistance to myovirus ΦSA012 (53). Missense mutations in guanylate kinase and the alpha subunit of DNA-dependent RNA polymerase conferred resistance but not corresponding decreases in adsorption rate, suggesting some post-adsorption role in resisting infection. More phage resistance systems likely remain undiscovered. A genome-wide association study of 207 clinical MRSA strains and 12 phage preparations identified 167 gene families putatively associated with phage-bacterial interactions (131). While these families included restriction-modification genes,

transcriptional regulators, and genes of prophage and SaPI origin, most were accessory gene families of unknown function.

Phage host range in *Staphylococcus* is determined by a hierarchical combination of host factors

In summary, we have described how host range of a *Staphylococcus* phage is determined by a combination of both host and phage-encoded genes, as well as the epigenetic DNA methylation patterns conferred on its DNA from the last strain it infected. Bacterial encoded factors can be conceived as affecting host range at different levels within the species (**Figure 3**). At the highest level, most phages' target for receptor binding (WTA) is highly conserved across *Staphylococcus* species. Strains with unusual WTAs, such as *S. aureus* ST395 and CoNS strains with poly-GroP WTA (55, 56), would be expected to be genetically isolated within the genus. Type I and IV R-M HsdS allotypes and capsule type are conserved between most strains of the same CC but differ between isolates of different CC groups and thus contribute to defining host range in a large subset of *S. aureus* strains. At the level of individual strains, inserted prophages and SaPIs, Stk2, type II systems acquired by HGT, and other as yet unknown functions may all serve to limit host range. We know even less about phage-encoded systems that counteract host resistance. The finding that lytic phages (*Myoviridae* and *Podoviridae*) tend to have broader host ranges than *Siphoviridae* when challenged against the same set of *Staphylococcus* strains suggests the former encode an array of uncharacterized genes that work against host defenses.

Future directions

Although much progress has been made in the past five decades toward understanding the mechanisms that define staphylococcal phage host range, numerous important questions remain. We need to know more about species other than *S. aureus* and *S. epidermidis*, and even within these species, we need to make sure that rarer and non-methicillin resistant strains are included in studies (132). We also need to ensure that our collections reflect the true diversity of phages that infect *Staphylococcus* species. Even within the two main species only a relatively small number of phages have been tested. This will lead us to consider the

questions of phage ecology when understanding what types of phages are found in different environments and with what abundance.

Discovering novel phage resistance mechanisms would aid the effort to understand determinants of host range. Many phage resistance mechanisms have been identified and characterized in other Gram-positives and other bacteria generally but not in the staphylococci. Superinfection exclusion (Sie) and abortive infection (Abi) systems, for example, are well-characterized in the lactococci (133–135). In addition, a recent publication describes some 26 new anti-phage defense systems identified in bacteria (136), not including the recently discovered bacteriophage exclusion (BREX) and defense island system associated with restriction-modification (DISARM) phage defenses (137–139). Six of the ten verified, newly discovered anti-phage defense systems (Thoeris, Hachiman, Gabija, Septu, Lamassu, and Kiwa) have orthologs in staphylococcal genomes (136).

Understanding phage host range to the point that we can make accurate predictions based on the host genome will be important for developing phage therapies against *Staphylococcus* strains. Ideally, cocktail formulations for therapy consist of phages with broad, non-overlapping host ranges against the target species (or clonal complex) to be treated. As there are many more genome sequences available than strains that can be tested for sensitivity in the laboratory (e.g > 40,000 for *S. aureus*) (140), with a predictive model we could run *in silico* tests on genome sequences to model the efficacy of the cocktail. With the potential for genome sequencing to be used in the future as a primary clinical diagnostic, we could modify the cocktail to contain phages that specifically target the bacterium causing the infection.

Knowledge of phage host range will also lead us to understand the fitness costs of resistance and its potential trade-offs with virulence and antibiotic resistance of *Staphylococcus*. Strains with null mutations in biosynthetic genes are rare, given WTA's roles in cell division, autolysis, virulence, and antibiotic resistance (36, 37). Although knocking out the genes involved in the first two steps of WTA biosynthesis has no fitness cost in *S. aureus* (at least in laboratory conditions) (141, 142), WTA has many critical physiological roles, especially in environments subject to phage therapy. Staphylococcal WTA is required for nasal colonization (141, 143), cell division (41, 43), regulating autolysis (144, 145), lysozyme resistance through cell wall crosslinking (132, 146), resistance to cationic antimicrobial peptides and fatty acids (147, 148), and biofilm formation (149). WTA-altered or negative phage-resistant mutants would in turn become less virulent (43) and

even antibiotic sensitive – highly unfit in the natural habitat colonizing mammalian hosts or in an infection site subject to treatment. Given that methicillin resistance requires WTA (50), phage/beta-lactam combination therapies could be particularly promising. Mutants resistant to either phage or beta-lactams would be sensitive to the other treatment, assuming the infecting strain is sensitive to the phage treatment. Nonetheless, as we note for host range, strains containing minor but fitness-neutral resistance mechanisms, such as R-M systems – rather than costly mutations – may be the most recalcitrant to phage therapy. Staphylococcal phage therapies must then overcome both immediate, emerging mutational resistance and intrinsic resistance mechanisms (e.g., R-M systems) specific to strains or clonal complexes. These resistance limitations, however, could be overcome by selecting phage host range mutants that escaped host resistance mechanisms, thus isolating more useful phages that would form more effective phage cocktails (150, 151).

Phage-resistant mutants isolated so far, such as those described in the adsorption studies, were typically selected in rich, aerated laboratory medium. The consequences for fitness of the same mutations occurring during *in vivo* infection might be more severe. In addition, both the relevance of various resistance mechanisms *in vivo* and the effect of strain genetic background on resistance selection - especially on a species-wide scale – have been left unexamined in most previous work. One study in mammalian hosts showed that environment altered phage transfer frequency and selection (152), leading to spread of prophage and selection of phage resistance by superimmunity. In laboratory media, phage transfer frequency was lower and spread of prophage was less pronounced (152). It will be important to know both how quickly and in which loci mutations emerge as well as the more general distribution of resistance gene families.

Finally, it is interesting to consider what phage host range studies reveal about the hosts themselves. Staphylococci seem to be unusual among Gram-positives in requiring conserved WTA receptors for attachment and having no reported role for protein receptors. Differences in the outer surface of *Staphylococcus* and/or a feature of the phage ecology within the genus requiring highly conserved receptors may account for this fact. Another interesting question is why CRISPRs play a much-reduced role for intercepting extrinsic phage DNA than R-M systems in this genus compared to other bacteria. It could be that CRISPR systems have a finite capacity for carrying fragments of mobile genetic elements, while R-M systems can attack a wider range of incoming DNA, relevant to rapidly evolving populations. Future studies that probe

435 these questions may reveal some of the differential evolutionary forces that shape the genomes of pathogenic
436 bacteria.

437 Conclusions

438 Staphylococcal phage resistance mechanisms have been identified at three stages of infection
439 (attachment, biosynthesis, and assembly) and regulate host range in a hierarchical manner depending on
440 mechanism conservation. Nonetheless, staphylococcal phage-bacterial interactions certainly present many
441 open questions that must be addressed to accurately develop and evaluate possible phage therapies. We
442 need further studies to objectively identify the contribution of individual phage resistance mechanisms to host
443 range. Such work would provide the information needed not only to formulate phage cocktails effective against
444 a wide variety of strains but also to overcome remaining obstacles to cocktail development (e.g., highly
445 effective R-M or Abi systems). Future studies relevant to phage therapy should also characterize phage
446 resistance development during infection and therapy as well as the effects of resistance on mutant fitness.
447 Taken together, this future work will inform the rational design of phage cocktails to treat staphylococcal
448 infections alone or in combination with antibiotics.

449 Acknowledgments

450 We thank Michelle Su and Robert Petit for critically reading the manuscript and providing helpful comments.
451 AGM was supported by the National Science Foundation (NSF) Graduate Research Fellowship Program
452 (GRFP). JAL was supported by the Medical Research Council (grant MR/P028322/1). TDR was supported by
453 the National Institutes of Health (NIH) grant R21 AI121860.

454 References

455 1. Kluytmans J, Belkum A van, Verbrugh H. 1997. Nasal carriage of Staphylococcus aureus: epidemiology,
456 underlying mechanisms, and associated risks. Clin Microbiol Rev 10:505–520.

457 2. Kong EF, Johnson JK, Jabra-Rizk MA. 2016. Community-Associated Methicillin-Resistant
458 Staphylococcus aureus: An Enemy amidst Us. PLOS Pathogens 12:e1005837.

459 3. Bagnoli F, Bertholet S, Grandi G. 2012. Inferring Reasons for the Failure of Staphylococcus aureus
460 Vaccines in Clinical Trials. Front Cell Infect Microbiol 2.

461 4. Wang I-N, Smith DL, Young R. 2000. Holins: The Protein Clocks of Bacteriophage Infections. Annu Rev
462 Microbiol 54:799–825.

463 5. Young R, Bläsi U. 1995. Holins: form and function in bacteriophage lysis. FEMS Microbiology Reviews
464 17:195–205.

465 6. Loessner MJ. 2005. Bacteriophage endolysins — current state of research and applications. Current
466 Opinion in Microbiology 8:480–487.

467 7. Pirisi A. 2000. Phage therapy—advantages over antibiotics? The Lancet 356:1418.

468 8. Nobrega FL, Costa AR, Kluskens LD, Azeredo J. 2015. Revisiting phage therapy: new applications for
469 old resources. Trends in Microbiology 23:185–191.

470 9. Stone R. 2002. Stalin's Forgotten Cure. Science 298:728–731.

471 10. Bradbury J. 2004. "My enemy's enemy is my friend." The Lancet 363:624–625.

472 11. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. 2010. Phage Therapy in
473 Clinical Practice: Treatment of Human Infections. Current Pharmaceutical Biotechnology 11:69–86.

474 12. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement
475 antibiotics. Trends in Biotechnology 28:591–595.

476 13. Sulakvelidze A, Alavidze Z, Morris JG. 2001. Bacteriophage Therapy. Antimicrob Agents Chemother
477 45:649–659.

478 14. Lu TK, Koeris MS. 2011. The next generation of bacteriophage therapy. Current Opinion in Microbiology
479 14:524–531.

480 15. Ly-Chatain MH. 2014. The factors affecting effectiveness of treatment in phages therapy. Front Microbiol
481 5.

16. Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV, Soler C, Fevre C, Arnaud I, Bretaudeau L, Gabard J. 2018. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. The Lancet Infectious Diseases.

17. Xia G, Wolz C. 2014. Phages of Staphylococcus aureus and their impact on host evolution. Infection, Genetics and Evolution 21:593–601.

18. Deghorain M, Van Melderen L. 2012. The Staphylococci Phages Family: An Overview. Viruses 4:3316–3335.

19. Alves DR, Gaudion A, Bean JE, Esteban PP, Arnot TC, Harper DR, Kot W, Hansen LH, Enright MC, Jenkins ATA. 2014. Combined Use of Bacteriophage K and a Novel Bacteriophage To Reduce Staphylococcus aureus Biofilm Formation. Appl Environ Microbiol 80:6694–6703.

20. Hsieh S-E, Lo H-H, Chen S-T, Lee M-C, Tseng Y-H. 2011. Wide Host Range and Strong Lytic Activity of Staphylococcus aureus Lytic Phage Stau2. Appl Environ Microbiol 77:756–761.

21. Synnott AJ, Kuang Y, Kurimoto M, Yamamichi K, Iwano H, Tanji Y. 2009. Isolation from Sewage Influent and Characterization of Novel Staphylococcus aureus Bacteriophages with Wide Host Ranges and Potent Lytic Capabilities. Appl Environ Microbiol 75:4483–4490.

22. O'Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A. 2005. Potential of the Polyvalent Anti-Staphylococcus Bacteriophage K for Control of Antibiotic-Resistant Staphylococci from Hospitals. Appl Environ Microbiol 71:1836–1842.

23. Gutiérrez D, Briers Y, Rodríguez-Rubio L, Martínez B, Rodríguez A, Lavigne R, García P. 2015. Role of the Pre-neck Appendage Protein (Dpo7) from Phage vB_SepiS-phiIPLA7 as an Anti-biofilm Agent in Staphylococcal Species. Front Microbiol 6.

24. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S. 2003.

Experimental Protection of Mice against Lethal Staphylococcus aureus Infection by Novel Bacteriophage ϕMR11. J Infect Dis 187:613–624.

25. Wills QF, Kerrigan C, Soothill JS. 2005. Experimental Bacteriophage Protection against Staphylococcus aureus Abscesses in a Rabbit Model. Antimicrobial Agents and Chemotherapy 49:1220–1221.

26. Verstappen KM, Tulinski P, Duim B, Fluit AC, Carney J, Nes A van, Wagenaar JA. 2016. The Effectiveness of Bacteriophages against Methicillin-Resistant Staphylococcus aureus ST398 Nasal Colonization in Pigs. PLOS ONE 11:e0160242.

27. Chen J, Quiles-Puchalt N, Chiang YN, Bacigalupe R, Fillol-Salom A, Chee MSJ, Fitzgerald JR, Penadés JR. 2018. Genome hypermobility by lateral transduction. Science 362:207–212.

28. Novick RP, Christie GE, Penadés JR. 2010. The phage-related chromosomal islands of Gram-positive bacteria. Nat Rev Microbiol 8:541–551.

29. McCarthy AJ, Witney AA, Lindsay JA. 2012. Staphylococcus aureus Temperate Bacteriophage: Carriage and Horizontal Gene Transfer is Lineage Associated. Front Cell Infect Microbiol 2.

30. Carroll JD, Cafferkey MT, Coleman DC. 1993. Serotype F double- and triple-converting phage insertionally inactivate the Staphylococcus aureusβ-toxin determinant by a common molecular mechanism. FEMS Microbiology Letters 106:147–155.

31. Iandolo JJ, Worrell V, Groicher KH, Qian Y, Tian R, Kenton S, Dorman A, Ji H, Lin S, Loh P, Qi S, Zhu H, Roe BA. 2002. Comparative analysis of the genomes of the temperate bacteriophages φ11, φ12 and φ13 of Staphylococcusaureus 8325. Gene 289:109–118.

32. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317–327.

33. Hyman P, Abedon ST. 2010. Bacteriophage Host Range and Bacterial Resistance. Advances in Applied Microbiology 70:217–248.

529 34. Allison GE, Klaenhammer TR. 1998. Phage Resistance Mechanisms in Lactic Acid Bacteria.
530 International Dairy Journal 8:207–226.

531 35. Xia G, Corrigan RM, Winstel V, Goerke C, Gründling A, Peschel A. 2011. Wall Teichoic Acid-Dependent
532 Adsorption of Staphylococcal Siphovirus and Myovirus. J Bacteriol 193:4006–4009.

533 36. Xia G, Kohler T, Peschel A. 2010. The wall teichoic acid and lipoteichoic acid polymers of
534 Staphylococcus aureus. International Journal of Medical Microbiology 300:148–154.

535 37. Brown S, Santa Maria JP, Walker S. 2013. Wall Teichoic Acids of Gram-Positive Bacteria. Annu Rev
536 Microbiol 67.

537 38. Shaw DRD, Mirelman D, Chatterjee AN, Park JT. 1970. Ribitol Teichoic Acid Synthesis in
538 Bacteriophage-resistant Mutants of Staphylococcus aureus H. J Biol Chem 245:5101–5106.

539 39. Shaw DRD, Chatterjee AN. 1971. O-Acetyl Groups as a Component of the Bacteriophage Receptor on
540 Staphylococcus aureus Cell Walls. J Bacteriol 108:584–585.

541 40. Chatterjee AN. 1969. Use of Bacteriophage-resistant Mutants to Study the Nature of the Bacteriophage
542 Receptor Site of Staphylococcus aureus. J Bacteriol 98:519–527.

543 41. Chatterjee AN, Mirelman D, Singer HJ, Park JT. 1969. Properties of a Novel Pleiotropic Bacteriophage-
544 Resistant Mutant of Staphylococcus aureus H1. J Bacteriol 100:846–853.

545 42. NCTC 3000 Project.

546 43. Capparelli R, Nocerino N, Lanzetta R, Silipo A, Amoresano A, Giangrande C, Becker K, Blaiotta G,
547 Evidente A, Cimmino A, Iannaccone M, Parlato M, Medaglia C, Roperto S, Roperto F, Ramunno L,
548 Iannelli D. 2010. Bacteriophage-Resistant Staphylococcus aureus Mutant Confers Broad Immunity
549 against Staphylococcal Infection in Mice. PLOS ONE 5:e11720.

550 44. Nair D, Memmi G, Hernandez D, Bard J, Beaume M, Gill S, Francois P, Cheung AL. 2011. Whole-
551 Genome Sequencing of Staphylococcus aureus Strain RN4220, a Key Laboratory Strain Used in

552 Virulence Research, Identifies Mutations That Affect Not Only Virulence Factors but Also the Fitness of
553 the Strain. Journal of Bacteriology 193:2332–2335.

554 45. Li X, Gerlach D, Du X, Larsen J, Stegger M, Kühner P, Peschel A, Xia G, Winstel V. 2015. An accessory
555 wall teichoic acid glycosyltransferase protects Staphylococcus aureus from the lytic activity of
556 Podoviridae. Sci Rep 5.

557 46. Xia G, Maier L, Sanchez-Carballo P, Li M, Otto M, Holst O, Peschel A. 2010. Glycosylation of wall
558 teichoic acid in Staphylococcus aureus by TarM. J Biol Chem 285:13405–13415.

559 47. Sobhanifar S, Worrall LJ, Gruninger RJ, Wasney GA, Blaukopf M, Baumann L, Lameignere E,
560 Solomonson M, Brown ED, Withers SG, Strynadka NCJ. 2015. Structure and mechanism of
561 Staphylococcus aureus TarM, the wall teichoic acid α-glycosyltransferase. Proc Natl Acad Sci USA
562 112:E576-585.

563 48. Sobhanifar S, Worrall LJ, King DT, Wasney GA, Baumann L, Gale RT, Nosella M, Brown ED, Withers
564 SG, Strynadka NCJ. 2016. Structure and Mechanism of Staphylococcus aureus TarS, the Wall Teichoic
565 Acid β-glycosyltransferase Involved in Methicillin Resistance. PLOS Pathogens 12:e1006067.

566 49. Li X, Koç C, Kühner P, Stierhof Y-D, Krismer B, Enright MC, Penadés JR, Wolz C, Stehle T, Cambillau
567 C, Peschel A, Xia G. 2016. An essential role for the baseplate protein Gp45 in phage adsorption to
568 Staphylococcus aureus. Sci Rep 6.

569 50. Brown S, Xia G, Luhachack LG, Campbell J, Meredith TC, Chen C, Winstel V, Gekeler C, Irazoqui JE,
570 Peschel A, Walker S. 2012. Methicillin resistance in Staphylococcus aureus requires glycosylated wall
571 teichoic acids. PNAS 109:18909–18914.

572 51. Qian Z, Yin Y, Zhang Y, Lu L, Li Y, Jiang Y. 2006. Genomic characterization of ribitol teichoic acid
573 synthesis in Staphylococcus aureus: genes, genomic organization and gene duplication. BMC Genomics
574 7:74.

52. Cerca N, Oliveira R, Azeredo J. Susceptibility of Staphylococcus epidermidis planktonic cells and biofilms to the lytic action of staphylococcus bacteriophage K. Letters in Applied Microbiology 45:313–317.

53. Azam AH, Hoshiga F, Takeuchi I, Miyanaga K, Tanji Y. 2018. Analysis of phage resistance in Staphylococcus aureus SA003 reveals different binding mechanisms for the closely related Twort-like phages ϕSA012 and ϕSA039. Appl Microbiol Biotechnol 1–15.

54. Gerlach D, Guo Y, Castro CD, Kim S-H, Schlatterer K, Xu F-F, Pereira C, Seeberger PH, Ali S, Codée J, Sirisarn W, Schulte B, Wolz C, Larsen J, Molinaro A, Lee BL, Xia G, Stehle T, Peschel A. 2018. Methicillin-resistant Staphylococcus aureus alters cell wall glycosylation to evade immunity. Nature 1.

55. Winstel V, Sanchez-Carballo P, Holst O, Xia G, Peschel A. 2014. Biosynthesis of the Unique Wall Teichoic Acid of Staphylococcus aureus Lineage ST395. mBio 5:e00869-14.

56. Winstel V, Liang C, Sanchez-Carballo P, Steglich M, Munar M, Bröker BM, Penadés JR, Nübel U, Holst O, Dandekar T, Peschel A, Xia G. 2013. Wall teichoic acid structure governs horizontal gene transfer between major bacterial pathogens. Nature Communications 4:2345.

57. Kaneko J, Narita-Yamada S, Wakabayashi Y, Kamio Y. 2009. Identification of ORF636 in Phage φSLT Carrying Panton-Valentine Leukocidin Genes, Acting as an Adhesion Protein for a Poly(Glycerophosphate) Chain of Lipoteichoic Acid on the Cell Surface of Staphylococcus aureus. J Bacteriol 191:4674–4680.

58. Baptista C, Santos MA, São-José C. 2008. Phage SPP1 reversible adsorption to Bacillus subtilis cell wall teichoic acids accelerates virus recognition of membrane receptor YueB. J Bacteriol 190:4989–4996.

59. Duerkop BA, Huo W, Bhardwaj P, Palmer KL, Hooper LV. 2016. Molecular Basis for Lytic Bacteriophage Resistance in Enterococci. mBio 7:e01304-16.

60. Mazmanian SK, Liu G, Ton-That H, Schneewind O. 1999. Staphylococcus aureus Sortase, an Enzyme that Anchors Surface Proteins to the Cell Wall. Science 285:760–763.

61. Ton-That H, Liu G, Mazmanian SK, Faull KF, Schneewind O. 1999. Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. PNAS 96:12424–12429.

62. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. 2008. Genome Sequence of Staphylococcus aureus Strain Newman and Comparative Analysis of Staphylococcal Genomes: Polymorphism and Evolution of Two Major Pathogenicity Islands. Journal of Bacteriology 190:300–310.

63. Bae T, Baba T, Hiramatsu K, Schneewind O. 2006. Prophages of Staphylococcus aureus Newman and their contribution to virulence. Molecular Microbiology 62:1035–1047.

64. Nordström K, Forsgren A. 1974. Effect of Protein A on Adsorption of Bacteriophages to Staphylococcus aureus. J Virol 14:198–202.

65. Wilkinson BJ, Holmes KM. 1979. Staphylococcus aureus cell surface: capsule as a barrier to bacteriophage adsorption. Infect Immun 23:549–552.

66. Sutra L, Audurier A, Poutrel B. 1988. Relationship between capsular types 5 and 8 and phage types in Staphylococcus aureus isolates from cow, goat and ewe milk. FEMS Microbiol Lett 55:83–85.

67. Sompolinsky D, Samra Z, Karakawa WW, Vann WF, Schneerson R, Malik Z. 1985. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol 22:828–834.

68. O'Riordan K, Lee JC. 2004. Staphylococcus aureus Capsular Polysaccharides. Clin Microbiol Rev 17:218–234.

69. Ohshima Y, Schumacher-Perdreau F, Peters G, Pulverer G. 1988. The role of capsule as a barrier to bacteriophage adsorption in an encapsulated Staphylococcus simulans strain. Med Microbiol Immunol 177:229–233.

70. O'Gara JP. 2007. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol Lett 270:179–188.

624 71. Götz F. 2002. Staphylococcus and biofilms. Molecular Microbiology 43:1367–1378.

625 72. McCourt J, O'Halloran DP, McCarthy H, O'Gara JP, Geoghegan JA. 2014. Fibronectin-binding proteins
626 are required for biofilm formation by community-associated methicillin-resistant Staphylococcus aureus
627 strain LAC. FEMS Microbiol Lett 353:157–164.

628 73. O'Neill E, Pozzi C, Houston P, Humphreys H, Robinson DA, Loughman A, Foster TJ, O'Gara JP. 2008.
629 A Novel Staphylococcus aureus Biofilm Phenotype Mediated by the Fibronectin-Binding Proteins,
630 FnBPA and FnBPB. Journal of Bacteriology 190:3835–3850.

631 74. Geoghegan JA, Corrigan RM, Gruszka DT, Speziale P, O'Gara JP, Potts JR, Foster TJ. 2010. Role of
632 Surface Protein SasG in Biofilm Formation by Staphylococcus aureus. Journal of Bacteriology
633 192:5663–5673.

634 75. Kelly D, McAuliffe O, Ross RP, Coffey A. Prevention of Staphylococcus aureus biofilm formation and
635 reduction in established biofilm density using a combination of phage K and modified derivatives. Letters
636 in Applied Microbiology 54:286–291.

637 76. Curtin JJ, Donlan RM. 2006. Using Bacteriophages To Reduce Formation of Catheter-Associated
638 Biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50:1268–1275.

639 77. Gutiérrez D, Martínez B, Rodríguez A, García P. 2012. Genomic characterization of two Staphylococcus
640 epidermidis bacteriophages with anti-biofilm potential. BMC Genomics 13:228.

641 78. Resch A, Fehrenbacher B, Eisele K, Schaller M, Götz F. Phage release from biofilm and planktonic
642 Staphylococcus aureus cells. FEMS Microbiology Letters 252:89–96.

643 79. Kameyama L, Fernandez L, Calderon J, Ortiz-Rojas A, Patterson TA. 1999. Characterization of Wild
644 Lambdoid Bacteriophages: Detection of a Wide Distribution of Phage Immunity Groups and Identification
645 of a Nus-Dependent, Nonlambdoid Phage Group. Virology 263:100–111.

646 80. Berngruber TW, Weissing FJ, Gandon S. 2010. Inhibition of Superinfection and the Evolution of Viral
647 Latency. J Virol 84:10200–10208.

81. Goerke C, Pantucek R, Holtfreter S, Schulte B, Zink M, Grumann D, Bröker BM, Doskar J, Wolz C. 2009. Diversity of Prophages in Dominant Staphylococcus aureus Clonal Lineages. Journal of Bacteriology 191:3462–3468.

82. Wilson GG, Murray NE. 1991. Restriction and Modification Systems. Annual Review of Genetics 25:585–627.

83. Sadykov MR. 2014. Restriction–Modification Systems as a Barrier for Genetic Manipulation of Staphylococcus aureus, p. 9–23. *In* Bose, JL (ed.), The Genetic Manipulation of Staphylococci. Springer New York, New York, NY.

84. Monk IR, Shah IM, Xu M, Tan M-W, Foster TJ. 2012. Transforming the Untransformable: Application of Direct Transformation To Manipulate Genetically Staphylococcus aureus and Staphylococcus epidermidis. mBio 3:e00277-11.

85. Monk IR, Foster TJ. 2012. Genetic manipulation of Staphylococci – Breaking through the barrier. Front Cell Infect Microbiol 2.

86. Costa SK, Donegan NP, Corvaglia A-R, François P, Cheung AL. 2017. Bypassing the Restriction System To Improve Transformation of Staphylococcus epidermidis. J Bacteriol 199.

87. Roberts RJ, Vincze T, Posfai J, Macelis D. 2015. REBASE—a database for DNA restriction and modification: enzymes, genes and genomes. Nucleic Acids Res 43:D298–D299.

88. Waldron DE, Lindsay JA. 2006. Sau1: a Novel Lineage-Specific Type I Restriction-Modification System That Blocks Horizontal Gene Transfer into Staphylococcus aureus and between S. aureus Isolates of Different Lineages. J Bacteriol 188:5578–5585.

89. Roberts GA, Houston PJ, White JH, Chen K, Stephanou AS, Cooper LP, Dryden DTF, Lindsay JA. 2013. Impact of target site distribution for Type I restriction enzymes on the evolution of methicillin-resistant Staphylococcus aureus (MRSA) populations. Nucleic Acids Res 41:7472–7484.

90. Cooper LP, Roberts GA, White JH, Luyten YA, Bower EKM, Morgan RD, Roberts RJ, Lindsay JA, Dryden DTF. 2017. DNA target recognition domains in the Type I restriction and modification systems of Staphylococcus aureus. Nucleic Acids Res 45:3395–3406.

91. Stegger M, Lindsay JA, Moodley A, Skov R, Broens EM, Guardabassi L. 2011. Rapid PCR Detection of Staphylococcus aureus Clonal Complex 398 by Targeting the Restriction-Modification System Carrying sau1-hsdS1. Journal of Clinical Microbiology 49:732–734.

92. Xu S, Corvaglia AR, Chan S-H, Zheng Y, Linder P. 2011. A type IV modification-dependent restriction enzyme SauUSI from Staphylococcus aureus subsp. aureus USA300. Nucleic Acids Res 39:5597–5610.

93. Veiga H, Pinho MG. 2009. Inactivation of the SauI Type I Restriction-Modification System Is Not Sufficient To Generate Staphylococcus aureus Strains Capable of Efficiently Accepting Foreign DNA. Appl Environ Microbiol 75:3034–3038.

94. Seeber S, Kessler C, Götz F. 1990. Cloning, expression and characterization of the Sau3AI restriction and modification genes in Staphylococcus carnosus TM300. Gene 94:37–43.

95. Sussenbach JS, Steenbergh PH, Rost JA, van Leeuwen WJ, van Embden JD. 1978. A second site-specific restriction endonuclease from Staphylococcus aureus. Nucleic Acids Res 5:1153–1163.

96. Dempsey RM. 2005. Sau42I, a BcgI-like restriction-modification system encoded by the Staphylococcus aureus quadruple-converting phage 42. Microbiology 151:1301–1311.

97. Lebenka Ai, Rachkus I. 1989. [DNA-methylase Sau 3A: isolation and various properties]. Biokhimiia 54:1009–1014.

98. Tock MR, Dryden DT. 2005. The biology of restriction and anti-restriction. Current Opinion in Microbiology 8:466–472.

99. O'Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald GF, Ross RP. 2004. Genome of Staphylococcal Phage K: a New Lineage of Myoviridae Infecting Gram-Positive Bacteria with a Low G+C Content. Journal of Bacteriology 186:2862–2871.

100. Iida S, Streiff MB, Bickle TA, Arber W. 1987. Two DNA antirestriction systems of bacteriophage P1, darA, and darB: characterization of darA− phages. Virology 157:156–166.

101. Kruger DH, Barcak GJ, Reuter M, Smith HO. 1988. EcoRII can be activated to cleave refractory DNA recognition sites. Nucleic Acids Res 16:3997–4008.

102. Zabeau M, Friedman S, Van Montagu M, Schell J. 1980. The ral gene of phage λ. Molec Gen Genet 179:63–73.

103. Studier FW, Movva NR. 1976. SAMase gene of bacteriophage T3 is responsible for overcoming host restriction. Journal of Virology 19:136–145.

104. Zavilgelsky GB, Kotova VY, Rastorguev SM. 2008. Comparative analysis of anti-restriction activities of ArdA (CollB-P9) and Ocr (T7) proteins. Biochemistry Moscow 73:906.

105. McMahon SA, Roberts GA, Johnson KA, Cooper LP, Liu H, White JH, Carter LG, Sanghvi B, Oke M, Walkinshaw MD, Blakely GW, Naismith JH, Dryden DTF. 2009. Extensive DNA mimicry by the ArdA anti-restriction protein and its role in the spread of antibiotic resistance. Nucleic Acids Res 37:4887–4897.

106. Sansevere EA, Robinson DA. 2017. Staphylococci on ICE: Overlooked agents of horizontal gene transfer. Mobile Genetic Elements 7:1–10.

107. Barrangou R, Marraffini LA. 2014. CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity. Molecular Cell 54:234–244.

108. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. 2007. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes. Science 315:1709–1712.

109. Li Q, Xie X, Yin K, Tang Y, Zhou X, Chen Y, Xia J, Hu Y, Ingmer H, Li Y, Jiao X. 2016. Characterization of CRISPR-Cas system in clinical Staphylococcus epidermidis strains revealed its potential association with bacterial infection sites. Microbiological Research 193:103–110.

718 110. Yang S, Liu J, Shao F, Wang P, Duan G, Yang H. 2015. Analysis of the features of 45 identified
719 CRISPR loci in 32 Staphylococcus aureus. Biochemical and Biophysical Research Communications
720 464:894–900.

721 111. Carte J, Wang R, Li H, Terns RM, Terns MP. 2008. Cas6 is an endoribonuclease that generates guide
722 RNAs for invader defense in prokaryotes. Genes Dev 22:3489–3496.

723 112. Jiang F, Doudna JA. 2015. The structural biology of CRISPR-Cas systems. Current Opinion in Structural
724 Biology 30:100–111.

725 113. Gasiunas G, Barrangou R, Horvath P, Siksnys V. 2012. Cas9–crRNA ribonucleoprotein complex
726 mediates specific DNA cleavage for adaptive immunity in bacteria. PNAS 109:E2579–E2586.

727 114. Kinnevey PM, Shore AC, Brennan GI, Sullivan DJ, Ehricht R, Monecke S, Slickers P, Coleman DC.
728 2013. Emergence of Sequence Type 779 Methicillin-Resistant Staphylococcus aureus Harboring a
729 Novel Pseudo Staphylococcal Cassette Chromosome mec (SCCmec)-SCC-SCCCRISPR Composite
730 Element in Irish Hospitals. Antimicrob Agents Chemother 57:524–531.

731 115. Gill SR, Fouts DE, Archer GL, Mongodin EF, DeBoy RT, Ravel J, Paulsen IT, Kolonay JF, Brinkac L,
732 Beanan M, Dodson RJ, Daugherty SC, Madupu R, Angiuoli SV, Durkin AS, Haft DH, Vamathevan J,
733 Khouri H, Utterback T, Lee C, Dimitrov G, Jiang L, Qin H, Weidman J, Tran K, Kang K, Hance IR,
734 Nelson KE, Fraser CM. 2005. Insights on Evolution of Virulence and Resistance from the Complete
735 Genome Analysis of an Early Methicillin-Resistant Staphylococcus aureus Strain and a Biofilm-
736 Producing Methicillin-Resistant Staphylococcus epidermidis Strain. J Bacteriol 187:2426–2438.

737 116. Marraffini LA, Sontheimer EJ. 2008. CRISPR Interference Limits Horizontal Gene Transfer in
738 Staphylococci by Targeting DNA. Science 322:1843–1845.

739 117. Bondy-Denomy J, Garcia B, Strum S, Du M, Rollins MF, Hidalgo-Reyes Y, Wiedenheft B, Maxwell KL,
740 Davidson AR. 2015. Multiple mechanisms for CRISPR–Cas inhibition by anti-CRISPR proteins. Nature
741 526:136–139.

742 118. Pawluk A, Staals RHJ, Taylor C, Watson BNJ, Saha S, Fineran PC, Maxwell KL, Davidson AR. 2016.
743 Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. Nature
744 Microbiology 1:16085.

745 119. Maxwell KL. 2016. Phages Fight Back: Inactivation of the CRISPR-Cas Bacterial Immune System by
746 Anti-CRISPR Proteins. PLOS Pathogens 12:e1005282.

747 120. Rauch BJ, Silvis MR, Hultquist JF, Waters CS, McGregor MJ, Krogan NJ, Bondy-Denomy J. 2017.
748 Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. Cell 168:150-158.e10.

749 121. Lindsay JA, Ruzin A, Ross HF, Kurepina N, Novick RP. 1998. The gene for toxic shock toxin is carried
750 by a family of mobile pathogenicity islands in Staphylococcus aureus. Molecular Microbiology 29:527–
751 543.

752 122. Seed KD. 2015. Battling Phages: How Bacteria Defend against Viral Attack. PLOS Pathogens
753 11:e1004847.

754 123. Ram G, Chen J, Kumar K, Ross HF, Ubeda C, Damle PK, Lane KD, Penadés JR, Christie GE, Novick
755 RP. 2012. Staphylococcal pathogenicity island interference with helper phage reproduction is a
756 paradigm of molecular parasitism. PNAS 109:16300–16305.

757 124. Ruzin A, Lindsay J, Novick RP. 2001. Molecular genetics of SaPI1 – a mobile pathogenicity island in
758 Staphylococcus aureus. Molecular Microbiology 41:365–377.

759 125. Damle PK, Wall EA, Spilman MS, Dearborn AD, Ram G, Novick RP, Dokland T, Christie GE. 2012. The
760 roles of SaPI1 proteins gp7 (CpmA) and gp6 (CpmB) in capsid size determination and helper phage
761 interference. Virology 432:277–282.

762 126. Úbeda Carles, Maiques Elisa, Barry Peter, Matthews Avery, Tormo María Ángeles, Lasa Íñigo, Novick
763 Richard P., Penadés José R. 2007. SaPI mutations affecting replication and transfer and enabling
764 autonomous replication in the absence of helper phage. Molecular Microbiology 67:493–503.

765 127. Poliakov A, Chang JR, Spilman MS, Damle PK, Christie GE, Mobley JA, Dokland T. 2008. Capsid size
766 determination by Staphylococcus aureus pathogenicity island SaPI1 involves specific incorporation of
767 SaPI1 proteins into procapsids. J Mol Biol 380:465–475.

768 128. Ram G, Chen J, Ross HF, Novick RP. 2014. Precisely modulated pathogenicity island interference with
769 late phage gene transcription. Proc Natl Acad Sci U S A 111:14536–14541.

770 129. Frígols B, Quiles-Puchalt N, Mir-Sanchis I, Donderis J, Elena SF, Buckling A, Novick RP, Marina A,
771 Penadés JR. 2015. Virus Satellites Drive Viral Evolution and Ecology. PLoS Genet 11.

772 130. Depardieu F, Didier J-P, Bernheim A, Sherlock A, Molina H, Duclos B, Bikard D. 2016. A Eukaryotic-like
773 Serine/Threonine Kinase Protects Staphylococci against Phages. Cell Host & Microbe 20:471–481.

774 131. Zschach H, Larsen MV, Hasman H, Westh H, Nielsen M, Międzybrodzki R, Jończyk-Matysiak E, Weber-
775 Dąbrowska B, Górski A. 2018. Use of a Regression Model to Study Host-Genomic Determinants of
776 Phage Susceptibility in MRSA. Antibiotics (Basel) 7.

777 132. Atilano ML, Pereira PM, Yates J, Reed P, Veiga H, Pinho MG, Filipe SR. 2010. Teichoic acids are
778 temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus. PNAS
779 107:18991–18996.

780 133. Mahony J, McGrath S, Fitzgerald GF, van Sinderen D. 2008. Identification and Characterization of
781 Lactococcal-Prophage-Carried Superinfection Exclusion Genes. Appl Environ Microbiol 74:6206–6215.

782 134. Sun X, Göhler A, Heller KJ, Neve H. 2006. The ltp gene of temperate Streptococcus thermophilus phage
783 TP-J34 confers superinfection exclusion to Streptococcus thermophilus and Lactococcus lactis. Virology
784 350:146–157.

785 135. Chopin M-C, Chopin A, Bidnenko E. 2005. Phage abortive infection in lactococci: variations on a theme.
786 Current Opinion in Microbiology 8:473–479.

787 136. Doron S, Melamed S, Ofir G, Leavitt A, Lopatina A, Keren M, Amitai G, Sorek R. 2018. Systematic
788 discovery of antiphage defense systems in the microbial pangenome. Science eaar4120.

137. Goldfarb T, Sberro H, Weinstock E, Cohen O, Doron S, Charpak-Amikam Y, Afik S, Ofir G, Sorek R. 2015. BREX is a novel phage resistance system widespread in microbial genomes. The EMBO Journal 34:169–183.

138. Barrangou R, van der Oost J. 2015. Bacteriophage exclusion, a new defense system. EMBO J 34:134–135.

139. Ofir G, Melamed S, Sberro H, Mukamel Z, Silverman S, Yaakov G, Doron S, Sorek R. 2018. DISARM is a widespread bacterial defence system with broad anti-phage activities. Nat Microbiol 3:90–98.

140. Petit III RA, Read TD. 2018. Staphylococcus aureus viewed from the perspective of 40,000+ genomes. PeerJ 6:e5261.

141. Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, Gross M, Nicholson G, Neumeister B, Mond JJ, Peschel A. 2004. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nature Medicine 10:243–245.

142. D'Elia MA, Henderson JA, Beveridge TJ, Heinrichs DE, Brown ED. 2009. The N-Acetylmannosamine Transferase Catalyzes the First Committed Step of Teichoic Acid Assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 191:4030–4034.

143. Winstel V, Kühner P, Salomon F, Larsen J, Skov R, Hoffmann W, Peschel A, Weidenmaier C. 2015. Wall Teichoic Acid Glycosylation Governs Staphylococcus aureus Nasal Colonization. mBio 6:e00632-15.

144. Schlag M, Biswas R, Krismer B, Kohler T, Zoll S, Yu W, Schwarz H, Peschel A, Götz F. 2010. Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl. Molecular Microbiology 75:864–873.

145. Biswas R, Martinez RE, Göhring N, Schlag M, Josten M, Xia G, Hegler F, Gekeler C, Gleske A-K, Götz F, Sahl H-G, Kappler A, Peschel A. 2012. Proton-binding capacity of Staphylococcus aureus wall teichoic acid and its role in controlling autolysin activity. PLoS ONE 7:e41415.

146. Bera A, Biswas R, Herbert S, Kulauzovic E, Weidenmaier C, Peschel A, Götz F. 2007. Influence of Wall Teichoic Acid on Lysozyme Resistance in Staphylococcus aureus. J Bacteriol 189:280–283.

147. Kohler T, Weidenmaier C, Peschel A. 2009. Wall Teichoic Acid Protects Staphylococcus aureus against Antimicrobial Fatty Acids from Human Skin. J Bacteriol 191:4482–4484.

148. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Götz F. 1999. Inactivation of the dlt Operon in Staphylococcus aureus Confers Sensitivity to Defensins, Protegrins, and Other Antimicrobial Peptides. J Biol Chem 274:8405–8410.

149. Holland LM, Conlon B, O'Gara JP. 2011. Mutation of tagO reveals an essential role for wall teichoic acids in Staphylococcus epidermidis biofilm development. Microbiology 157:408–418.

150. Yu L, Wang S, Guo Z, Liu H, Sun D, Yan G, Hu D, Du C, Feng X, Han W, Gu J, Sun C, Lei L. 2018. A guard-killer phage cocktail effectively lyses the host and inhibits the development of phage-resistant strains of Escherichia coli. Appl Microbiol Biotechnol 102:971–983.

151. Gu J, Liu X, Li Y, Han W, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R, Sun C, Feng X. 2012. A Method for Generation Phage Cocktail with Great Therapeutic Potential. PLOS ONE 7:e31698.

152. McCarthy AJ, Loeffler A, Witney AA, Gould KA, Lloyd DH, Lindsay JA. 2014. Extensive Horizontal Gene Transfer during Staphylococcus aureus Co-colonization In Vivo. Genome Biol Evol 6:2697–2708.

835

836

837

838

839

840

841 ## Figures

842 Figure 1: Stages of phage infection and corresponding examples of resistance mechanisms at each stage.

843 Examples not yet identified in the staphylococci are listed in red.



844
845
846
847
848
849
850

851 Figure 2: A - The structure of the staphylococcal cell envelope. Lipoteichoic acid is shown in orange (glycerol
852 phosphate), a surface protein in black, wall teichoic acid in orange (glycerol phosphate) and yellow (ribitol
853 phosphate), capsule in blue, and cell wall carbohydrates in green (N-acetylglucosamine – GlcNAc) and purple
854 (N-acetylmuramic acid – MurNAc). Staphylococcal phages bind WTA and/or its ribitol phosphate modifications

(i.e., GlcNAc). B – Outline of the wall teichoic acid (WTA) biosynthesis pathway with proteins corresponding to each step listed in the blue arrows. Abbreviations are defined as follows - C_{55}-P, undecaprenyl phosphate; GlcNAc, N-acetylglucosamine; UDP-GlcNAc, uridine-5-diphosphate-N-acetylglucosamine; ManNAc, N-acetylmannosamine; UDP-ManNAc, uridine-5-diphosphate-N-acetylmannosamine; Gro-P, glycerol phosphate; CDP-Gro, cytidyl diphosphate-glycerol; Rbo-P, ribitol phosphate; CDP-Rbo, cytidyl diphosphate-ribitol; ABC, ATP-binding cassette; and LCP, LytR-CpsA-Psr.



Figure 3: Phage host range for an individual strain is the combination of multiple factors that have different levels of conservation within the species. This is illustrated by a hypothetical phylogenetic tree. Mechanisms can be present throughout strains (1, most conserved – red), present in many strains but with considerable allelic variation (2, conserved but polymorphic – shades of green), or present in a few strains, possibly with allelic variation (3a-3c, less conserved with potential polymorphism – blue, purple, and yellow). Branches

where mechanisms evolved by mutation or homologous recombination in the case of 1 and 2 or were acquired by HGT, in the case of 3a-3c, are annotated with colored stars. The table on the right summarizes the mechanisms (1-3c) present in each strain (A-J) using shaded boxes with corresponding colors. Strain J has a mutation that results in the null phenotype for the red mechanism. Host range is the result of the combination of mechanisms present, so strains A-C as well as F, H, and I would be predicted to have identical host ranges, but phage-specific factors could also introduce variability.